The Daily Biotech Pulse: Moderna’s Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
LAVA Therapeutics Reports FDA Orphan Drug Designation For LAVA-051 For Treatment Of Chronic Lymphocytic Leukemia
LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company’s CD1d
Lava Therapeutics Granted FDA Orphan Drug Designation For Treatment Of Chronic Lymphocytic Leukemia
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=821821
LAVA Therapeutics To Present Bispecific Gamma Delta T Cell Engagers For Treatment Of Cancer At 2021 AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics
LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that
SVB Leerink Maintains Outperform on LAVA Therapeutics, Lowers Price Target to $24
SVB Leerink analyst Daina Graybosch maintains LAVA Therapeutics (NASDAQ:LVTX) with a Outperform and lowers the price target from $26 to $24.
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
